Ignite Creation Date:
2024-05-05 @ 4:58 PM
Last Modification Date:
2024-10-26 @ 9:26 AM
Study NCT ID:
NCT00358917
Status:
COMPLETED
Last Update Posted:
2011-04-11
First Post:
2006-07-28
Brief Title:
Study of LopinavirRitonavir Tablets Comparing Once-Daily Versus Twice-Daily Administration When Coadministered With NucleosideNucleotide Reverse Transcriptase Inhibitors in Antiretroviral-Experienced Human Immunodeficiency Virus Type 1 Infected Subjects
Sponsor:
Abbott
Organization:
Abbott
Study Overview
Official Title:
A Phase 3 Randomized Open-Label Study of LopinavirRitonavir LPVr Tablets 800200 Milligram mg Once-Daily QD Versus 400100 mg Twice-Daily BID When Coadministered With NucleosideNucleotide Reverse Transcriptase Inhibitors NRTIs in Antiretroviral-Experienced Human Immunodeficiency Virus Type 1 HIV-1 Infected Subjects
Status:
COMPLETED
Status Verified Date:
2011-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study was to compare the safety tolerability and antiviral activity of once-daily QD and twice-daily BID dosing of the lopinavirritonavir LPVr tablet formulation in combination with nucleosidenucleotide reverse transcriptase inhibitors NRTIs in antiretroviral-experienced human immunodeficiency virus type 1 infected subjects with detectable viral load while receiving their current antiretroviral therapy
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None